The current market of optogenetics is in its nascent stages, it is still restricted to the laboratory and animal models. However, the technology, which had been classified as the “method of the year” in 2010, holds great potential to deal with the rising cases of neurodegenerative, cardiac, and infectious diseases. Optogenetics is going to pave the way for scientists to pinpoint the function of thousands of different types of neurons among the roughly 86 billion present in the human brain. It holds the ability to turn largely co-relational fields of science into one that tests causation.

The metabolomics is currently an up-growing ‘OMICS’ approach, for therapeutic interventions, where this technology is being increasingly adopted for biomarker discovery, in tandem with genomics, for better understating of underlying causes of pathology. The present status of metabolomics promises healthy growth opportunities in biomarkers and genomics- based research. As several companies and universities are focusing on the research related to early and better diagnosis of a diseases, as well as improved treatment option, the metabolic pathways are well- explored at the academic and a biopharmaceutical R&D level.

The global gene therapy market is currently being driven by various factors, including the rising investments in the R&D activities, technological advancements, and growing prevalence of target diseases. The recent approvals of few gene therapies have created a promising future for the market. Also, most of the regulatory authorities are focusing on the approval of safe and efficient gene therapies. The major market players are collaborating with the academic and research institutes, which is boosting the R&D in this field. Currently, among the gene therapy products in development, recombinant adeno-associated virus (AAV)- based vectors are the most widely used ones and they show the highest potential for delivery in gene therapy indications. While the majority (around 74%) of AAV-based therapeutic products are in the process of clinical development (early to mid-phase), several promising clinical outputs have helped in progressing the pipeline of possible AAV-based products.

Biosolids provide an eco-friendly way of reducing the dependence on hazardous chemical fertilizers in agricultural applications. The application of these biosolids not only reduces the need for chemical fertilizers, but also enhances the agricultural output. Biosolids are a valuable source of nutrients, although they contain lower N (2–8%), P (1.5–3%), and K (0.1–0.6%), compared to commercial fertilizers, especially the high- grade ones. Biosolids provide micronutrients, including copper (Cu), boron (B), iron (Fe), zinc (Zn), and molybdenum (Mo), which are essential plant nutrients that are not available in most conventional chemical fertilizers. As more wastewater plants become capable of producing high-quality biosolids, there is greater opportunity to make use of this valuable resource to improve soil fertility and increase crop yield.

Biometrics-as-a-Service facilitates cloud-based identification and authentication for an enterprise to identify an individual through their biological and behavioral characteristics. The technology offers multiple advantages such as easy implementation at any endpoint on the network, accessible from anywhere across the globe and reduced subscription costs. Rise in complex IoT landscape, growing number of cyber-attacks, and increase in demand for cost-efficient biometric solutions among different industry verticals and increase in the adoption of cloud-based biometrics are the factors that mainly drive the biometrics-as-a-service (BaaS) market growth. However, privacy concerns and security issues pertaining to the data stored on the cloud hinder the biometrics- as-a-service market growth. Moreover, advanced technology integrations in cloud-based biometric solutions and growing cloud industry in developing economies are expected to offer lucrative opportunities for the biometrics-as-a-service industry during the forecast period.

There has been a considerable shift in the lifestyles and diet habits of people, over the past two decades. Urbanization and consumerism drove this shift, leading to a rapid rise in the consumption of artificial and synthetic food products, which has resulted in increased incidence of lifestyle diseases. Consumers are aware of the ingredients used in food and beverage and they are gradually moving toward functional foods and beverages, which is promoted as beneficial basic nutrition. These products are purported to provide optimal nutrition and reduce the risk of disease occurrence.

Crude oil and natural gas are the major sources of energy for the automotive industries since many decades. Due to the negative environmental impact by the increasing consumption of crude oil and natural gas worldwide, and high crude oil prices, biofuels, such as bioethanol, are considered as a successful alternative for crude oil and natural gas as a fuel for automotive industries. • Ethanol is the lowest cost octane with octane rating of 113, providing strategies to save lots of money for both manufacturers and consumers. The bioethanol market is directly affected by the consumption of fuel. Since past four decades, ethanol remains as an effective tool to reduce harmful emissions from the automotive. As ethanol is a pure compound with 35% oxygen, it burns more cleanly and completely than petroleum products. Ethanol helps to reduce emissions of air toxics, carbon monoxide, particulate matter, nitrous oxides, and exhaust hydrocarbons, by displacing aromatics in petroleum products.

12 月18 日和19 日我们参加了英伟达GTC China 2019 大会。英伟达CEO 黄仁勋在会上发表主题演讲，并发布多项软硬件新产品。其中，下一代机器人处理器Orin SoC 的性能，提升为前代产品Xavier 的7 倍，以及计算图优化编译器TensorRT7 支持RNN，可以更好地支持会话AI。此外，英伟达技术团队以及英伟达的各类合作伙伴，在两天的分论坛和展会中，介绍了AI 及英伟达软硬件平台在自动驾驶、机器人、金融、医疗、科学计算等领域中的应用和最新进展。